FDA
-
-
-
-
-
-
-
Akeso's ivonescimab beats durvalumab in biliary tract cancer trial
-
-
-
-
-
-
-
Summit Therapeutics plc (SMMT) PT Lowered to $38 at Guggenheim
-
-
-
-
-
-
-
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
-
-
-
-
-
-
-
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON
-
-
-
-
-
-
-
Jefferies Downgrades Summit Therapeutics plc (SMMT) to Hold
-
-
-
-
-
-
-
Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens
-
-
-
-
-
-
-
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
331,677 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

